September 16, 2008 – Health Canada has granted Bayer HealthCare marketing authorization for the anticoagulant Xarelto® (rivaroxaban), taken as one tablet, once-daily, for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip or total knee replacement surgery.
The details can be read here.
No comments:
Post a Comment